New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene TestingGlobeNewsWire • 06/08/20
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast CancerGlobeNewsWire • 06/04/20
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to PatientsGlobeNewsWire • 05/29/20
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T.GlobeNewsWire • 05/28/20
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker StudyGlobeNewsWire • 05/26/20
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 05/20/20
Myriad's Ovarian Cancer Test Approved, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 05/13/20
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian CancerGlobeNewsWire • 05/11/20
Myriad Genetics, Inc. (MYGN) CEO Bryan Riggsbee on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive DisorderGlobeNewsWire • 04/20/20
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus PandemicGlobeNewsWire • 04/08/20
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOCGlobeNewsWire • 04/06/20
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate CancerGlobeNewsWire • 03/30/20
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate CancerGlobeNewsWire • 03/18/20